US0053291078 - ADR
ADAGENE INC-ADR
NASDAQ:ADAG (9/28/2023, 7:00:00 PM)
1.47
-0.05 (-3.29%)
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 248 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
ADAGENE INC-ADR
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Suzhou JIANGSU 215123
P: 8651287773632.0
CEO: Peter (Peizhi) Luo
Employees: 248
Website: https://www.adagene.com/
– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies – ...
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated...
SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...
Here you can normally see the latest stock twits on ADAG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: